Learning from nemolizumab: A  promising therapy for prurigo nodularis
A recent phase 3 clinical trial (OLYMPIA 2) of nemolizumab, an anti –IL-31RA mAb for prurigo nodularis (PN), met the key primary end points of efficacy at week 16 and demonstrated benefit across all 5 secondary end points. Some of the more striking results were at the early time point of week 4, with significantly more patients reaching at least a 4-point reductio n in the Peak Pruritus Numerical Rating Scale itch score, almost complete itch relief (Peak Pruritus Numerical Rating Scale  (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 7, 2024 Category: Allergy & Immunology Authors: Brian S. Kim Tags: Editorial Source Type: research

A randomized double-blinded trial to assess recurrence of systemic allergic reactions following COVID-19 mRNA vaccination
Systemic allergic reactions (sARs) following coronavirus disease 2019 (COVID-19) mRNA vaccines were initially reported at a higher rate than after traditional vaccines. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 7, 2024 Category: Allergy & Immunology Authors: Muhammad B. Khalid, Ellen Zektser, Eric Chu, Min Li, Joanna Utoh, Patrick Ryan, Hanna S. Loving, Roa Harb, Robbie Kattappuram, Lindsay Chatman, Stella Hartono, Estefania Claudio-Etienne, Guangping Sun, Edward P. Feener, Zhongbo Li, Samuel K. Lai, Quang Le Source Type: research

Learnings from Nemolizumab: A Promising Therapy for Prurigo Nodularis
(Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 7, 2024 Category: Allergy & Immunology Authors: Brian S. Kim Source Type: research

Neutralizing IgG4 antibodies are a biomarker of sustained efficacy after peanut oral immunotherapy
(Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 7, 2024 Category: Allergy & Immunology Authors: Tarun Keswani, Nicole A. LaHood, Orlee Marini-Rapoport, Bijoya Karmakar, L éna Andrieux, Brian Reese, Sunny L. Sneed, Lars C. Pedersen, Geoffrey A. Mueller, Sarita U. Patil Source Type: research

Early Skin Inflammatory Biomarker is Predictive of Development and Persistence of Atopic Dermatitis in Infants
The STOP AD study, a randomized, open-label trial evaluating the effect of short-term (first four postnatal days to 8 weeks) skin barrier protection using AVEENO ® Dermexa Fast& Long-Lasting Balm in infants with a parent with allergic disease, demonstrated decreased cumulative incidence and decreased prevalence of AD at 12 months of age. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 7, 2024 Category: Allergy & Immunology Authors: Georgios N. Stamatas, Takahiro Sato, Carol N í Chaoimh, Thierry Oddos, Richard Insel, Jonathan O’B. Hourihane, Alan D. Irvine Source Type: research

“A randomized double-blinded trial to assess recurrence of systemic allergic reactions following COVID-19 mRNA vaccination”
Systemic allergic reactions (sARs) following coronavirus disease-2019 (COVID-19) mRNA vaccines were initially reported at a higher rate than traditional vaccines. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 7, 2024 Category: Allergy & Immunology Authors: Muhammad B. Khalid, Ellen Zektser, Eric Chu, Min Li, Joanna Utoh, Patrick Ryan, Hanna S. Loving, Roa Harb, Robbie Kattappuram, Lindsay Chatman, Stella Hartono, Estefania Claudio-Etienne, Guangping Sun, Edward P. Feener, Zhongbo Li, Samuel K. Lai, Quang Le Source Type: research

Atopic dermatitis phenotype affects expression of atopic diseases despite similar mononuclear cell cytokine response
The atopic march refers to the coexpression and progression of atopic diseases in childhood, often beginning with atopic dermatitis (AD), although children may not progress through each atopic disease. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 2, 2024 Category: Allergy & Immunology Authors: Mohamed H. Taki, Kristine E. Lee, Ronald Gangnon, James E. Gern, Robert F. Lemanske, Daniel J. Jackson, Anne Marie Singh Source Type: research

Skin Biomarkers Predict the Development of Food Allergy in Early Life
Lipid and cytokine levels in the stratum corneum at the age of 2 months selectively predict with high probability the future onset of food allergy up to the age of 2 years. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 2, 2024 Category: Allergy & Immunology Authors: Evgeny Berdyshev, Jihyun Kim, Byung Eui Kim, Elena Goleva, Taras Lyubchenko, Irina Bronova, Anna Sofia Bronoff, Olivia Xiao, Sehun Jang, Sanghee Shin, Jeongmin Song, Jiwon Kim, Sukyung Kim, Boram Park, Kyunga Kim, Suk-Joo Choi, Soo-Young Oh, Kangmo Ahn, D Source Type: research

Loss-of-phosphorylation of IKZF1 results in gain-of-function associated with immune dysregulation
Capsule summary: A novel heterozygous mutation T398M in IKZF1 was identified in two patients with immune dysregulation symptoms. Our study shows that this mutation by impacting the phosphorylation of IKZF1 represents a novel gain-of-function mechanism by loss-of-phosphorylation (GOF-LOP). (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 2, 2024 Category: Allergy & Immunology Authors: Akihiro Hoshino, Beno ît Heid Picard, Sophia Polychronopoulou, Charikleia Kelaidi, Saba Azarnoush, Sven Kracker, Frédéric Rieux-Laucat, David Boutboul, Sylvain Latour Source Type: research

Atopic Dermatitis Phenotypes Impact Expression of Atopic Diseases Despite Similar Mononuclear Cell Cytokine Responses
The atopic march refers to the co-expression and progression of atopic diseases in childhood, often beginning with atopic dermatitis, although children may not “progress” through each atopic disease. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 2, 2024 Category: Allergy & Immunology Authors: Mohamed H. Taki, Kristine E. Lee, Ronald Gangnon, James E. Gern, Robert F. Lemanske, Daniel J. Jackson, Anne Marie Singh Source Type: research

Corrigendum
With regard to the article in the March 2021 issue entitled “Single-cell transcriptomic analysis reveals key immune cell phenotypes in the lungs of patients with asthma exacerbation” (J Allergy Clin Immunol 2021;147:941-54), the accession number for the original sequence data was not included. The GSA accession number is HRA005092 and the paper's data is available at: https://bigd.big.ac.cn/gsa-human/browse/HRA005092. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 1, 2024 Category: Allergy & Immunology Tags: Corrigendum Source Type: research

News beyond our pages
Deng et al (Cell 2023;186:5375-93.e25; https://doi.org/10.1016/j.cell.2023.10.019) identified an important role for direct activation of neurons by skin microbes in itch generation. More specifically, epicutaneous exposure to Staphylococcus aureus induced itch- and scratch-induced skin damage in mice. Mechanistically, S aureus secreted a serine protease, V8, which induced direct cleavage of proteinase-activated receptor 1 (PAR1) present on the surface of sensory neurons that mediate itch. Finally, PAR1 genetic deficiency or pharmacologic inhibition led to decreased S aureus-induced itch. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 1, 2024 Category: Allergy & Immunology Tags: News beyond our pages Source Type: research

Erratum
With regard to the article in the May 2022 issue entitled “Thunderstorm asthma in seasonal allergic rhinitis: The TAISAR study” (J Allergy Clin Immunol 2022;149:1607-16), an editing error omitted the word “not” from the following sentence (see italicized text): “A total of 228 individuals were enrolled, of whom 35% (the I-SAR group [n = 80]) re ported isolated SAR, 37% (the O-TA group [n = 84]) had experienced TA symptoms but had not presented to the hospital, and 28% (the H-TA group [n = 64]) had presented to the hospital with TA.” The publisher apologizes for the error. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 1, 2024 Category: Allergy & Immunology Tags: Erratum Source Type: research

The Editors ’ Choice
Treatment options for itch are limited. Antihistamines represent the most widely available class of antipruritic drugs, with over $2 billion in sales per year for itch alone. However, antihistamines exhibit poor efficacy in most chronic itch conditions, even those associated with the histaminergic itch pathway like urticaria. Thus, itch is often classified dichotomously as either histaminergic or nonhistaminergic in nature. In this issue, Trier et  al (p 852) provide evidence that suggests that this canonical distinction is likely overly simplistic. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 1, 2024 Category: Allergy & Immunology Tags: The editors ’ choice Source Type: research

Cover 1
(Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - March 1, 2024 Category: Allergy & Immunology Source Type: research